Actinium Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (32)

Latest Posts

About This Stock More About This Stock
Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity
Article By: Jason Napodano
Monday, June 12, 2017 1:41 PM EDT
BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care.
In this article: ATNM
Read
EMA Gives Thumbs-Up To Actinium's Phase 3 SIERRA Program
Article By: Jason Napodano
Tuesday, March 21, 2017 10:07 AM EDT
Today's news is very positive for Actinium. Enrollment in SIERRA continues on plan and there are DMC updates expected around the middle of the year and again potentially at year end.
In this article: ATNM
Read
Actinium Offers Shareholders Several Interesting Near-Term Catalysts
Article By: Jason Napodano
Friday, February 24, 2017 12:50 PM EDT
Shares of ATNM have performed nicely over the past month, driven by the achievement of several milestones, including the hiring of a new Chief Medical Officer and initiation of a new clinical trial with Actimab-M for multiple ATNM​myeloma.
In this article: ATNM Also: SGEN
Read
What Does SGEN's Clinical Hold On CD33A Mean For Actinium?
Article By: Jason Napodano
Wednesday, January 4, 2017 5:35 PM EDT
The Seattle Genetic news to temporarily halt clinical work in some studies with CD33A is not a negative reflection on Actinium. It might, in fact, instead be an opportunity.
In this article: SGEN, ATNM
Read
ASH Abstract Confirms Positive Outlook For Actinium's Actimab-A
Article By: Jason Napodano
Wednesday, November 9, 2016 3:46 PM EDT
Actinium now has a validated safe and effective treatment for elderly patients with newly-diagnosed AML progressing in a Phase 2 clinical study. Importantly, the Phase 1 data shows that at 2 µCi/kg, the CR rate was 50%
In this article: ATNM
Read

PARTNER HEADLINES

Latest Tweets for $ATNM

No tweets yet!